Oncology Institute (NASDAQ:STLN) Major Shareholder Jorey Chernett Acquires 12,000 Shares

Oncology Institute, Inc. (NASDAQ:STLN) major shareholder Jorey Chernett acquired 12,000 shares of Oncology Institute stock in a transaction dated Friday, August 14th. The stock was purchased at an average cost of $6.54 per share, for a total transaction of $78,480.00. Following the completion of the purchase, the insider directly owned 10,660,858 shares in the company, valued at approximately $69,722,011.32. This represents a 0.11% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Oncology Institute Stock Down 2.2%

Shares of NASDAQ:STLN opened at $6.31 on Tuesday. Oncology Institute, Inc. has a 1 year low of $2.32 and a 1 year high of $7.05.

Wall Street Analyst Weigh In

Separately, Weiss Ratings assumed coverage on shares of Oncology Institute in a research note on Thursday, August 6th. They issued a “sell (d-)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Oncology Institute presently has an average rating of “Sell”.

About Oncology Institute

Oncology Institute is a physician-led healthcare company focused on delivering specialized cancer care through an integrated oncology platform. Its services are designed to support patients throughout the cancer-care journey, including diagnosis, treatment planning, chemotherapy and other medical oncology services, supportive care, and ongoing disease management.

The company’s business model emphasizes value-based oncology care, with care coordination and clinical programs intended to improve outcomes while managing the overall cost of treatment.